PDF(Pubmed)
Abstract：
Bruton\'s tyrosine kinase inhibitors (BTKis) have revolutionized the treatment of B-cell lymphomas. However, safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy. A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment. A multidisciplinary consensus working group was established, comprising 35 members from the fields of hematology, cardiovascular disease, cardio-oncology, clinical pharmacy, and evidence-based medicine. This evidence-based expert consensus was formulated using an evidence-based approach and the Delphi method. The Joanna Briggs Institute Critical Appraisal (JBI) tool and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach were used to rate the quality of evidence and grade the strength of recommendations, respectively. This consensus provides practical recommendations for BTKis medication based on nine aspects within three domains, including the management of common adverse drug events such as bleeding, cardiovascular events, and hematological toxicity, as well as the management of drug-drug interactions and guidance for special populations. This multidisciplinary expert consensus could contribute to promoting a multi-dimensional, comprehensive and standardized management of BTKis.
摘要：
布鲁顿的酪氨酸激酶抑制剂（BTKis）彻底改变了B细胞淋巴瘤的治疗。然而,与使用BTKis相关的安全问题可能会阻碍治疗的连续性,并进一步影响临床疗效.从药理学角度来看，缺乏与BTKi治疗相关的安全问题的全面和系统的专家共识。成立了一个多学科共识工作组,由来自血液学领域的35名成员组成，心血管疾病,心脏肿瘤学，临床药学,和循证医学。这种基于证据的专家共识是使用基于证据的方法和德尔菲法制定的。乔安娜·布里格斯研究所批判性评估(JBI)工具和建议评估分级，发展,采用评估(GRADE)方法对证据质量进行评级，对建议的强度进行评级，分别。该共识基于三个领域内的九个方面为BTKis药物提供了实用建议。包括常见药物不良事件的管理，如出血，心血管事件,和血液学毒性，以及对特殊人群的药物相互作用的管理和指导。这种多学科专家共识有助于促进多层面,BTKis的全面、规范管理。
